| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/30/2001 | WO2001009325A3 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 08/30/2001 | WO2001002540A3 Adenoviral vectors for treating disease |
| 08/30/2001 | WO2000074701A3 Method and composition for inhibiting cardiovascular cell proliferation |
| 08/30/2001 | WO2000071510A3 INHIBITORS OF FACTOR Xa |
| 08/30/2001 | WO2000041719A9 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | WO2000040614A9 Characterization of the soc/crac calcium channel protein family |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | US20010018522 Neuropeptide y receptor ligand |
| 08/30/2001 | US20010018521 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 08/30/2001 | US20010018456 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
| 08/30/2001 | US20010018451 Raloxifene, tamoxifen |
| 08/30/2001 | US20010018449 Hypotensive agent, endothelial damage, arteriosclerosis, antidiabetic agents |
| 08/30/2001 | US20010018447 Il-8 receptor antagonists |
| 08/30/2001 | US20010018445 Thalidomide |
| 08/30/2001 | US20010018439 Antidiabetic agents |
| 08/30/2001 | US20010018438 Nervous system disorders; psychological disorders |
| 08/30/2001 | US20010018434 Administering an antiestrogen compound |
| 08/30/2001 | US20010018429 Neurotransmitter |
| 08/30/2001 | US20010018426 Lithium chloride |
| 08/30/2001 | US20010018212 Molecular weight of 14,000 to 24,000 daltons; treating infectious diseases and malignant tumors with said protein |
| 08/30/2001 | US20010018198 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same |
| 08/30/2001 | US20010018054 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 08/30/2001 | US20010018050 Administering protein C; avoiding bleeding, toxicity and side effects of anticoagulant agents |
| 08/30/2001 | DE10008329A1 New aminosulfonyl-biphenyl derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or angina pectoris |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2401356A1 Combination drug |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | CA2401063A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 08/30/2001 | CA2401036A1 Pyridinylimidazoles |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400923A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400896A1 Novel compositions and uses of dictyostatin compounds |
| 08/30/2001 | CA2400892A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same |
| 08/30/2001 | CA2400875A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400874A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | CA2400867A1 Method of screening compounds for biological activity |
| 08/30/2001 | CA2400797A1 Therapeutic agents |
| 08/30/2001 | CA2400794A1 New transcription factor carp-2 |
| 08/30/2001 | CA2400622A1 Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| 08/30/2001 | CA2400485A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400215A1 Hla binding peptides and their uses |
| 08/30/2001 | CA2400040A1 Integrin antagonists |
| 08/30/2001 | CA2399418A1 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2399018A1 Aminosulfonylbiphenyl derivatives |
| 08/30/2001 | CA2397558A1 Dosing regimen |
| 08/30/2001 | CA2397234A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2396971A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2368447A1 Small molecule modulators of g protein-coupled receptor six |
| 08/30/2001 | CA2368382A1 Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient |
| 08/30/2001 | CA2368366A1 Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient |
| 08/30/2001 | CA2365606A1 Medicament for prevention or treatment of various diseases involving an increase in eosinophils chymase inhibitor as effective ingredient |
| 08/29/2001 | EP1127894A1 Method of diagnosis of transmissible spongiform encephalopathy (TSE) |
| 08/29/2001 | EP1127883A2 Oxamides as IMPDH inhibitors |
| 08/29/2001 | EP1127882A1 Tetrazole compounds as thyroid receptor ligands |
| 08/29/2001 | EP1127880A2 Phenylacetic acid derivatives substituted by a heterocycle and their use as A-II antagonists and as inhibitors of smooth muscle cell proliferation |
| 08/29/2001 | EP1127869A1 Novel compounds and medicinal use thereof |
| 08/29/2001 | EP1127582A2 Use of cladribine on a stent to prevent restenosis |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127573A1 Compostitions and methods for treating osteoporosis |
| 08/29/2001 | EP1127150A2 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| 08/29/2001 | EP1127132A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 08/29/2001 | EP1127131A2 Connective tissue growth factor (ctgf) and methods of use |
| 08/29/2001 | EP1127119A1 Compounds and methods for modulating claudin-mediated functions |
| 08/29/2001 | EP1127115A1 Antisense oligomer |
| 08/29/2001 | EP1127109A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 08/29/2001 | EP1127107A1 Methods for the production of tcr gamma delta t cells |
| 08/29/2001 | EP1127076A2 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 08/29/2001 | EP1127067A2 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
| 08/29/2001 | EP1127058A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 08/29/2001 | EP1127054A1 Novel inhibitors of impdh enzyme |
| 08/29/2001 | EP1127052A1 Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| 08/29/2001 | EP1127051A2 Tricyclic pyrazole derivatives |
| 08/29/2001 | EP1126878A1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 08/29/2001 | EP1126870A2 Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| 08/29/2001 | EP1126858A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells |
| 08/29/2001 | EP1126856A1 Compounds and their therapeutic use with diabetic complications |
| 08/29/2001 | EP1126850A1 Treatment of disorders of the outer retina |
| 08/29/2001 | EP1126846A1 Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder |
| 08/29/2001 | EP1126845A2 New use of immunosuppressants for mmp-mediated diseases |
| 08/29/2001 | EP1126844A1 Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation |
| 08/29/2001 | EP1126843A1 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| 08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
| 08/29/2001 | EP1126839A1 Substituted phenethylsulfones and method of reducing tnf alpha levels |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | EP1126835A1 Method for preventing increased iridial pigmentation during prostaglandin treatment |
| 08/29/2001 | EP1126832A2 Conductance of improperly folded proteins through the secretory pathway |
| 08/29/2001 | EP1126826A1 Multiparticulate modified release composition |
| 08/29/2001 | EP1126812A1 Treatment of skin with adenosine or adenosine analog |
| 08/29/2001 | EP0968168B1 Aromatic tetracyclic compounds of the retinoid type, method for preparing and use |
| 08/29/2001 | EP0889877B1 META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS |
| 08/29/2001 | EP0828758B1 Chimeric fatty body-pro-grf analogs with increased biological potency |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |